



1/22

FIG.1




RYLRIHPRSWVHQLRL



RYLRIHPRSWVHGIALRL


3/22

FIG.3




4/22

FIG. 4



5/22

FIG.5



6/22






FIG.7



8/22

FIG.8


SEQ ID NO:4



9/22

FIG.9

SEQ ID NO:16




10/22

FIG.10

(+)/(-) RATIO

0 1 3 10




BEST AVAILABLE COPY

11/22

FIG.11

 $(+)/(-)$ RATIO

0 1 2 3



12/22

FIG.12






FIG.13



13/22

FIG.14



14/22

FIG.15


	Bal 31(-)				Bal 31(+)			
SEQ ID NO:1	-	+	-	-	-	+	-	-
LIPOFECTIN	-	-	+	-	-	-	+	-
LIPOFECTAMINE 2000	-	-	-	+	-	-	-	+



15/22


FIG.16

(+)/(-) RATIO
CONTROL 0 1 2 3 5 10




16/22

FIG.17




17/22

FIG.18



18/22

FIG. 19



19/22

FIG.20






FIG.21



20/22

FIG.22



21/22

FIG.23




FIG.24




FIG.25

